Breaking Finance News

Zacks Investment Research downgraded Natera Inc (NASDAQ:NTRA) to Sell in a report released today.

Yesterday Natera Inc (NASDAQ:NTRA) traded 1.37% higher at $11.67. The company’s 50-day moving average is $11.89 and its 200-day moving average is $11.23. The last stock close price is up 5.32% from the 200-day moving average, compared to the S&P 500 which has decreased -0.04% over the same time. 0 shares of NTRA traded hands, down from an average trading volume of 215,795

Zacks Investment Research has downgraded Natera Inc (NASDAQ:NTRA) to Sell in a report released on 1/11/2017.

Recent Performance Chart

Natera Inc (NASDAQ:NTRA)

Natera Inc has 52 week low of $6.52 and a 52 week high of $13.80 and has a market capitalization of $0.

Also covering Natera Inc's target, a total of 5 equity analysts have released a research note on NTRA. The one year target is $17.60 with one equity analyst rating the company a strong buy, three equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.

General Company Details For Natera Inc (NASDAQ:NTRA)

Natera, Inc. is a diagnostics company. The Company's product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening (Horizon) to determine carrier status for various severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening (PGS) and Spectrum Pre-implantation Genetic Diagnosis (PGD) to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization (IVF) cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father(s).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *